FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening Security of Cancer Care in Europe MOST POPULAR Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ December 27, 2018 ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A... November 12, 2025 Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... February 13, 2023 Load more HOT NEWS KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,... Is there a future without Pap testing? COVID-19: “We’ve got so much on our plates” Liquid Biopsies for Cancer: What to Know and What to Expect
